Quantisnow Logo
Dashboard

Korro to Participate in Upcoming Investor Conferences

$KRRO
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $KRRO alert in real time by email

CAMBRIDGE, Mass., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO) a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that members of management will participate in the following investor conferences:

Piper Sandler 36th Annual Healthcare Conference

Ram Aiyar, Ph.D., Chief Executive Officer and President, will participate in a fireside chat on Tuesday, December 3, 2024, at 4:00 p.m. ET. Vineet Agarwal, Chief Financial Officer, and Kemi Olugemo, M.D., FAAN, Chief Medical Officer, will also participate in 1x1 investor meetings at the conference.

7th Annual Evercore ISI HealthCONx Conference

Dr. Aiyar will participate in a fireside chat on Wednesday, December 4, 2024, at 7:30 a.m. ET. Mr. Agarwal and Dr. Olugemo will also be participating at the conference.

Citi's 2024 Global Healthcare Conference

Dr. Aiyar, Mr. Agarwal, and Dr. Olugemo will participate in 1x1 investor meetings on Thursday, December 5, 2024.

Oppenheimer Movers in Rare Disease Summit

Dr. Aiyar will participate in a panel titled "Recent Progress on RNA Editing" on Thursday, December 12, 2024, at 3:40 p.m. ET. Mr. Agarwal will also be participating at the conference.

The live webcasts of the Piper Sandler and Evercore fireside chats can be accessed on the "Events & Presentations" page in the Investor section of Korro's website at www.korrobio.com. Following the presentations, a replay of the event will be available for 30 days.

About Korro

Korro is a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent diseases using its proprietary RNA editing platform. Korro is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to affect a precise yet transient single base edit. By editing RNA instead of DNA, Korro is expanding the reach of genetic medicines by delivering additional precision and tunability, which has the potential for increased specificity and improved long-term tolerability. Using an oligonucleotide-based approach, Korro expects to bring its medicines to patients by leveraging its proprietary platform with precedented delivery modalities, manufacturing know-how, and established regulatory pathways of approved oligonucleotide drugs. Korro is based in Cambridge, Massachusetts. For more information, visit korrobio.com.

Korro Contact Information

Investor & Media Contact

Tim Palmer

IR@korrobio.com 



Primary Logo

Get the next $KRRO alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Q&A

New

  • What is Korro Bio's primary focus?

    Korro Bio is focused on developing new genetic medicines based on RNA editing for both rare and common diseases.

  • When and where will Korro's CEO participate in a fireside chat?

    Dr. Ram Aiyar will participate in a fireside chat on December 3, 2024, at the Piper Sandler Annual Healthcare Conference.

  • What technology does Korro Bio use for its genetic medicine development?

    Korro's proprietary RNA editing platform is designed to create precise yet transient genetic edits, offering increased precision and improved tolerability.

  • Where can investors access the webcasts of Korro's investor presentations?

    The live webcasts of the fireside chats from the Piper Sandler and Evercore conferences will be accessible on Korro's website under the 'Events & Presentations' section.

  • What other conference is Korro participating in and what will be the focus of their panel?

    Korro Bio will also be participating in the Oppenheimer Movers in Rare Disease Summit with a focus on RNA editing advancements on December 12, 2024.

Recent Analyst Ratings for
$KRRO

DatePrice TargetRatingAnalyst
1/10/2025$155.00Outperform
Oppenheimer
10/21/2024$153.00Strong Buy
Raymond James
8/14/2024$180.00Outperform
William Blair
3/28/2024$100.00 → $115.00Buy
H.C. Wainwright
2/27/2024$120.00Outperform
BMO Capital Markets
12/4/2023$100.00Buy
H.C. Wainwright
11/29/2023$70.00Outperform
RBC Capital Mkts
11/10/2023$180.00Overweight
Piper Sandler
More analyst ratings

$KRRO
 Press Releases

Fastest customizable press release news feed in the world

See more

  • Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer

    CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, announced today the appointment of Loïc Vincent, Ph.D., as the Company's Chief Scientific Officer. "We are excited to welcome Dr. Vincent, whose extensive drug development experience and expertise in translating groundbreaking science into therapies will be instrumental in leading our scientific team and strategy," said Ram Aiyar, Ph.D., CEO and President of Korro. "He joins us at an important time as we advance multiple candidates i

    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Korro Reports Full Year 2024 Financial Results and Provides Business Updates

    —Completed dosing of first two cohorts in Phase 1/2a REWRITE Clinical Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD); Interim readout expected in the second half of 2025  —U.S. Food and Drug Administration (FDA) Granted Orphan Drug Designation to KRRO-110 for the treatment of AATD   —Executing 3-2-1 strategy through end of 2027 with the goal of establishing three clinical-stage development programs, targeting two tissue types with a single RNA-editing platform; Second development candidate expected to be announced in 2025  —Strengthened leadership team with the formation of Clinical Advisory Board and key additions to board and management team  —Ended 2024 with a strong balance

    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency

    CAMBRIDGE, Mass., March 14, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the investigational medicine KRRO-110 for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). "Receiving orphan drug designation from the FDA underscores the growing need for new treatments for patients living with AATD," said Kemi Olugemo, MD, Chief Medical Officer at Korro. "KRRO-110 has the potential to treat both liver and lung

    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

$KRRO
 Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$KRRO
 Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$KRRO
 Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$KRRO
 SEC Filings

See more

$KRRO
 Leadership Updates

Live Leadership Updates

See more

  • Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer

    CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, announced today the appointment of Loïc Vincent, Ph.D., as the Company's Chief Scientific Officer. "We are excited to welcome Dr. Vincent, whose extensive drug development experience and expertise in translating groundbreaking science into therapies will be instrumental in leading our scientific team and strategy," said Ram Aiyar, Ph.D., CEO and President of Korro. "He joins us at an important time as we advance multiple candidates i

    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • CAMP4 Appoints John Maraganore and Rachel Meyers as Strategic Advisors

    CAMBRIDGE, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels across a range of genetic diseases, today announced the appointments of John Maraganore, Ph.D., and Rachel Meyers, Ph.D., as strategic advisors to the Company. For nearly 20 years, Dr. Maraganore served as the founding Chief Executive Officer and Director of Alnylam where he led the company's programs in RNA interference through global commercialization, resulting in the launch of the first four RNAi th

    $CAMP
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Korro Reports Third Quarter 2024 Financial Results and Provides Business Updates

    - Submitted regulatory filing for first-in-human clinical study of KRRO-110 in patients with alpha-1 antitrypsin deficiency (AATD) - Formed Clinical Advisory Board (CAB) of leading lung and liver experts and strengthened leadership team - Partnered with Novo Nordisk to develop up to two targets for cardiometabolic diseases leveraging Korro's proprietary OPERATM platform - Ended third quarter of 2024 with $169.1 million in cash, cash equivalents and marketable securities - Cash runway into the second half of 2026 expected to fund KRRO-110 through completion of a Phase 1/2 clinical study and progress additional pipeline candidates CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Ko

    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

$KRRO
 Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more